HOMEINVESTORSPRESS ROOMCONTACTABOUT USDISEASE FOCUSINNOVATIONCLINICAL STUDIESPRESERVING FUNCTION AND QUALITY OF LIFE INTO OLD AGEAlzheimer’s DiseaseParkinson’s DiseaseABOUT USAboutWe are dedicated to the goal of preserving a person’s function and quality of life into old age. Our drug attacks neurodegeneration at its rootsQR Pharma is a specialty pharmaceutical company developing novel treatments for  Alzheimer’s, Parkinson’s and other neurodegenerative diseases. QR is attacking neurodegeneration at its roots with its product candidate Posiphen® which inhibits the production of brain toxic proteins.The economic burden and impact on wellness and quality of life for both patients and their caregivers in dementia is crushing. Today, existing drugs manage the symptoms and provide only marginal cost-benefit tradeoffs.DISEASE FOCUSOUR FOCUSNeurodegenerative diseases are the largest unmet need for our aging population, our economy and the world. QR Pharma understands how brain cells die in both slow chronic & fast acute injuries to the brain and the nervous system Alzheimer’s Disease (AD) A type of dementia that causes problems with memory, thinking and behavior. Symptoms usually develop slowly and get worse over time, becoming severe enough to interfere with daily tasks.Alzheimer’s DiseasePreviousNext5,400,000Estimated people in the US have Alzheimer’s disease (AD)Parkinson’s disease (PD):  A chronic and progressive movement disorder, meaning that symptoms continue and worsen over time. It involves the malfunction and death of vital nerve cells in the brain, called neurons.Parkinsons’s DiseasePreviousNext1,000,000Estimated people in the US have Parkinson’s disease (AD)INNOVATIONINNOVATIONAttacking Neurodegeneration at it’s RootsPosiphen®QR Pharma’s lead compound, Posiphen® inhibits synthesis of amyloid precursor protein (APP), Tau and α-Synuclein. Posiphen® is distinct from other Alzheimer’s disease (AD) drugs currently in development, because it inhibits the formation of toxic proteins before they are formedOur PipelineAlzheimer’s disease: QR is starting a 1 month phase IIa study in mild to moderate Alzheimer patients in June and expects the data to be available at the beginning of 2017Parkinson’s disease: human safety was completesTraumatic brain injury: human safety was completedPRESS ROOMWhat is happening at QR PharmaBEHIND THE SCIENCEPress ReleasesPress Release QR Pharma Announces New Scientific Advisory Board  with Appointment of World-Class Neurodegenerative Disease ExpertsJanuary 24, 2017Four Neurology Experts Join Advisory Board Following Recent Breakthrough…http://qrpharma.com/wp-content/uploads/2016/02/qr-pharma-logo-for-menu.png20002000scorch20http://qrpharma.com/wp-content/uploads/2016/04/qr-pharma-logo-for-menu-300x300.pngscorch202017-01-24 10:20:242017-01-24 14:03:30QR Pharma Announces New Scientific Advisory Board  with Appointment of World-Class Neurodegenerative Disease ExpertsPress Release QR Pharma